https://www.live-feeds.com/feed/roche-eli-lilly-s-alzheimer-s-blood-test-gets-fda-clearanceContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/roche-eli-lilly-s-alzheimer-s-blood-test-gets-fda-clearancehttps://www.live-feeds.com/feed/roche-eli-lilly-s-alzheimer-s-blood-test-gets-fda-clearance#u50653Fri, 28 Aug 2026 08:20:37 +0000The FDA cleared the Elecsys pTau217 blood test, developed by Roche and Eli Lilly, to identify amyloid pathology in adults with cognitive decline. Roche announced the approval on August 24. This single-biomarker tool provides a minimally invasive alternative for primary and specialty care providers to detect Alzheimer's signs earlier than previous methods. Labcorp and Quest Diagnostics intend to offer the test, which previously earned CE mark certification earlier this year.Why it mattersEarlier diagnostic methods often required more invasive procedures to identify amyloid pathology. This https://www.live-feeds.com/feed/roche-eli-lilly-s-alzheimer-s-blood-test-gets-fda-clearancehttps://www.live-feeds.com/feed/roche-eli-lilly-s-alzheimer-s-blood-test-gets-fda-clearance#u48469Tue, 25 Aug 2026 13:13:15 +0000The US Food and Drug Administration cleared the Elecsys pTau217 blood test developed by Roche and Eli Lilly to help identify signs of Alzheimer's disease. The test is intended for use in primary and specialty care to detect amyloid pathology in adults with cognitive decline. While some reports specify the test is for people aged 55 and older, other sources state it is approved for Americans as young as 40. The minimally invasive tool allows physicians to identify symptoms of the disease earlier than previous methods.Why it mattersAmyloid pathology is a primary characteristic of Alzheimer&